CLAIMS

1. Use of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of Alzheimer's disease, the treatment further comprising the use of an acetylcholinesterase inhibitor, wherein the Alzheimer's disease patient carries one or two ApoE4 alleles.

2. The use according to claim 1, wherein the pharmaceutically acceptable salt of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine is the hydrochloride salt.

3. The use according to any of claims 1-2, wherein the acetylcholinesterase inhibitor is selected from the group consisting of donepezil, rivastigmine and galantamine or pharmaceutically acceptable salts thereof.

4. The use according to any of claims 1-3, wherein the acetylcholinesterase inhibitor is the hydrochloride salt of donepezil.

5. The use according to any of claims 1-4, wherein pharmaceutically acceptable salt of N-(2-(6-fluoro-1H-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine is the hydrochloride salt and the acetylcholinesterase inhibitor is the hydrochloride salt of donepezil.

6. The use according to any of claims 1-5, wherein *N*-(2-(6-fluoro-*1H*-indol-3-yl)-ethyl)-3-(2,2,3,3-tetrafluoropropoxy)-benzylamine or the pharmaceutically acceptable salt thereof is to be administered in a dosing range from 60 mg/day to 120 mg/day.

7. The use according to any of claims 1-6, wherein the Alzheimer's disease patient is an APOE4 heterozygote patient.

8. The use according to any of claims 1-6, wherein the Alzheimer's disease patient is an APOE4/4 homozygote patient.

9. The use according to any of claims 1-6, wherein the Alzheimer's disease patient is an APOE4/4 homozygote patient diagnosed with mild to moderate Alzheimer's disease.

10. The use according to any of claims 1-6, wherein the Alzheimer's disease patient is an APOE4 heterozygote patient diagnosed with mild to moderate Alzheimer's disease.